Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity

A. M. Algotar, P. A. Thompson, J. Ranger-Moore, M. S. Stratton, Chiu-Hsieh Hsu, Frederick R Ahmann, Raymond B Nagle, Steven P Stratton

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Current diagnostic tools are inadequate for reliable prediction of prostate cancer (PCa) aggressiveness in patients with localised disease. This results in many patients being exposed to potentially unnecessary invasive treatment and its associated morbidities. In order to develop appropriate treatment strategies, it is essential to understand the differences between patients who will develop aggressive disease and those who will not. Methods: A longitudinal study was conducted in men with localised PCa on active surveillance for their disease in which 140 subjects were followed every 3months for up to 5years. Change in prostate-specific antigen (PSA) over time (PSA velocity) was used as a marker for PCa progression. Subjects were categorised as slow, intermediate and fast progressors based on tertiles of PSA velocity. Differences in baseline markers were investigated using logistic regressions. Two approaches were used, slow progressors were compared with fast progressors (model 1) and slow progressors were compared with combination of intermediate and fast progressors (model 2). Results: Aspirin was negatively associated with high PSA velocity in model 1 (odds ratio (95% confidence interval): 0.24 (0.06, 0.94), P-value = 0.04) and model 2 (odds ratio = 0.22 (0.08, 0.59), P-value = 0.003), whereas smoking was positively associated with high PSA velocity in model 1 (1.03 (0.92, 1.13), P-value = 0.01). Conclusions: These findings highlight the role of aspirin and smoking in PCa progression. They have potential towards risk stratification as well as PCa prevention and hence need to be investigated further.

Original languageEnglish (US)
Pages (from-to)374-380
Number of pages7
JournalInternal Medicine Journal
Volume42
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Aspirin
Smoking
Odds Ratio
Longitudinal Studies
Logistic Models
Confidence Intervals
Morbidity
Therapeutics

Keywords

  • Aspirin
  • Prostate cancer progression
  • PSA velocity
  • Smoking

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity. / Algotar, A. M.; Thompson, P. A.; Ranger-Moore, J.; Stratton, M. S.; Hsu, Chiu-Hsieh; Ahmann, Frederick R; Nagle, Raymond B; Stratton, Steven P.

In: Internal Medicine Journal, Vol. 42, No. 4, 04.2012, p. 374-380.

Research output: Contribution to journalArticle

@article{eaab255755ba4aecbd75a6f92cf6e07c,
title = "Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity",
abstract = "Background: Current diagnostic tools are inadequate for reliable prediction of prostate cancer (PCa) aggressiveness in patients with localised disease. This results in many patients being exposed to potentially unnecessary invasive treatment and its associated morbidities. In order to develop appropriate treatment strategies, it is essential to understand the differences between patients who will develop aggressive disease and those who will not. Methods: A longitudinal study was conducted in men with localised PCa on active surveillance for their disease in which 140 subjects were followed every 3months for up to 5years. Change in prostate-specific antigen (PSA) over time (PSA velocity) was used as a marker for PCa progression. Subjects were categorised as slow, intermediate and fast progressors based on tertiles of PSA velocity. Differences in baseline markers were investigated using logistic regressions. Two approaches were used, slow progressors were compared with fast progressors (model 1) and slow progressors were compared with combination of intermediate and fast progressors (model 2). Results: Aspirin was negatively associated with high PSA velocity in model 1 (odds ratio (95{\%} confidence interval): 0.24 (0.06, 0.94), P-value = 0.04) and model 2 (odds ratio = 0.22 (0.08, 0.59), P-value = 0.003), whereas smoking was positively associated with high PSA velocity in model 1 (1.03 (0.92, 1.13), P-value = 0.01). Conclusions: These findings highlight the role of aspirin and smoking in PCa progression. They have potential towards risk stratification as well as PCa prevention and hence need to be investigated further.",
keywords = "Aspirin, Prostate cancer progression, PSA velocity, Smoking",
author = "Algotar, {A. M.} and Thompson, {P. A.} and J. Ranger-Moore and Stratton, {M. S.} and Chiu-Hsieh Hsu and Ahmann, {Frederick R} and Nagle, {Raymond B} and Stratton, {Steven P}",
year = "2012",
month = "4",
doi = "10.1111/j.1445-5994.2011.02473.x",
language = "English (US)",
volume = "42",
pages = "374--380",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity

AU - Algotar, A. M.

AU - Thompson, P. A.

AU - Ranger-Moore, J.

AU - Stratton, M. S.

AU - Hsu, Chiu-Hsieh

AU - Ahmann, Frederick R

AU - Nagle, Raymond B

AU - Stratton, Steven P

PY - 2012/4

Y1 - 2012/4

N2 - Background: Current diagnostic tools are inadequate for reliable prediction of prostate cancer (PCa) aggressiveness in patients with localised disease. This results in many patients being exposed to potentially unnecessary invasive treatment and its associated morbidities. In order to develop appropriate treatment strategies, it is essential to understand the differences between patients who will develop aggressive disease and those who will not. Methods: A longitudinal study was conducted in men with localised PCa on active surveillance for their disease in which 140 subjects were followed every 3months for up to 5years. Change in prostate-specific antigen (PSA) over time (PSA velocity) was used as a marker for PCa progression. Subjects were categorised as slow, intermediate and fast progressors based on tertiles of PSA velocity. Differences in baseline markers were investigated using logistic regressions. Two approaches were used, slow progressors were compared with fast progressors (model 1) and slow progressors were compared with combination of intermediate and fast progressors (model 2). Results: Aspirin was negatively associated with high PSA velocity in model 1 (odds ratio (95% confidence interval): 0.24 (0.06, 0.94), P-value = 0.04) and model 2 (odds ratio = 0.22 (0.08, 0.59), P-value = 0.003), whereas smoking was positively associated with high PSA velocity in model 1 (1.03 (0.92, 1.13), P-value = 0.01). Conclusions: These findings highlight the role of aspirin and smoking in PCa progression. They have potential towards risk stratification as well as PCa prevention and hence need to be investigated further.

AB - Background: Current diagnostic tools are inadequate for reliable prediction of prostate cancer (PCa) aggressiveness in patients with localised disease. This results in many patients being exposed to potentially unnecessary invasive treatment and its associated morbidities. In order to develop appropriate treatment strategies, it is essential to understand the differences between patients who will develop aggressive disease and those who will not. Methods: A longitudinal study was conducted in men with localised PCa on active surveillance for their disease in which 140 subjects were followed every 3months for up to 5years. Change in prostate-specific antigen (PSA) over time (PSA velocity) was used as a marker for PCa progression. Subjects were categorised as slow, intermediate and fast progressors based on tertiles of PSA velocity. Differences in baseline markers were investigated using logistic regressions. Two approaches were used, slow progressors were compared with fast progressors (model 1) and slow progressors were compared with combination of intermediate and fast progressors (model 2). Results: Aspirin was negatively associated with high PSA velocity in model 1 (odds ratio (95% confidence interval): 0.24 (0.06, 0.94), P-value = 0.04) and model 2 (odds ratio = 0.22 (0.08, 0.59), P-value = 0.003), whereas smoking was positively associated with high PSA velocity in model 1 (1.03 (0.92, 1.13), P-value = 0.01). Conclusions: These findings highlight the role of aspirin and smoking in PCa progression. They have potential towards risk stratification as well as PCa prevention and hence need to be investigated further.

KW - Aspirin

KW - Prostate cancer progression

KW - PSA velocity

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=84859819988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859819988&partnerID=8YFLogxK

U2 - 10.1111/j.1445-5994.2011.02473.x

DO - 10.1111/j.1445-5994.2011.02473.x

M3 - Article

C2 - 21395960

AN - SCOPUS:84859819988

VL - 42

SP - 374

EP - 380

JO - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

IS - 4

ER -